These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11780700)

  • 1. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
    Aapro MS
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
    Mattson K; Saarinen A; Jekunen A
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in the management of advanced non-small cell lung cancer.
    Miller VA
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New options in the treatment of non-small cell lung cancer.
    Fossella F; Rigas JR; Belani CP
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 9. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
    Morere JF
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
    [No Abstract]   [Full Text] [Related]  

  • 10. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study shows 2-year survival advantage for docetaxel.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
    [No Abstract]   [Full Text] [Related]  

  • 12. [Gemcitabine].
    Takeda K
    Nihon Rinsho; 2002 May; 60 Suppl 5():359-65. PubMed ID: 12101689
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
    Postmus P
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
    Krug LM; Miller VA
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
    Oncology (Williston Park); 2002 Aug; 16(8):1052. PubMed ID: 12201644
    [No Abstract]   [Full Text] [Related]  

  • 16. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and docetaxel combinations in non-small cell lung cancer.
    Belani CP
    Chest; 2000 Apr; 117(4 Suppl 1):144S-151S. PubMed ID: 10777470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
    Waters JS; O'Brien ME
    Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Calvo AR; Belani CP
    Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.